HC Wainwright Has Bearish Outlook for KTTA FY2026 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Pasithea Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Nik now forecasts that the company will post earnings per share of ($1.86) for the year, down from their prior forecast of ($0.68). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($2.30) EPS.

Other research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised shares of Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Finally, Zacks Research upgraded shares of Pasithea Therapeutics to a “hold” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pasithea Therapeutics currently has an average rating of “Hold” and a consensus price target of $3.00.

Pasithea Therapeutics Stock Performance

Pasithea Therapeutics stock opened at $0.77 on Friday. Pasithea Therapeutics has a 52 week low of $0.28 and a 52 week high of $3.79. The stock has a market capitalization of $19.20 million, a P/E ratio of -0.22 and a beta of 0.25. The stock has a fifty day moving average of $0.79 and a 200-day moving average of $0.85.

Pasithea Therapeutics (NASDAQ:KTTA) last released its earnings results on Monday, March 30th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.71).

Institutional Investors Weigh In On Pasithea Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KTTA. Two Sigma Investments LP bought a new position in shares of Pasithea Therapeutics in the third quarter valued at approximately $26,000. Citadel Advisors LLC lifted its stake in Pasithea Therapeutics by 43.7% in the 3rd quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after purchasing an additional 20,483 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pasithea Therapeutics by 113.9% in the 4th quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after purchasing an additional 29,020 shares in the last quarter. Jane Street Group LLC boosted its holdings in Pasithea Therapeutics by 137.0% in the 4th quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock valued at $77,000 after purchasing an additional 34,319 shares during the period. Finally, AdvisorShares Investments LLC boosted its holdings in Pasithea Therapeutics by 33.1% in the 3rd quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company’s stock valued at $186,000 after purchasing an additional 64,149 shares during the period. Institutional investors own 23.92% of the company’s stock.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.